Study of large intestine in retention of faeces in relation with fecal calprotectin

Study of pakvashaya pertaining to purishaja udavarta with reference to investigation range of fecal calprotectin

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048079

Enrollment

120

Registered

2022-12-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K638- Other specified diseases of intestine

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Selected 120 diagnosed patients of purishaja udavarta

Exclusion criteria

Exclusion criteria: Patients below 40 years and above 60 years Avirecya Patients taken non-steroidal anti-inflammatory drugs.

Design outcomes

Primary

Measure	Time frame
Assessment of pakvashaya is possible on the basis of investigation range of fecal calprotectinTimepoint: 3 weeks	—

Secondary

Measure	Time frame
1.Relieving of Mala sang and reduction in sign and symptoms of purishaja udavarta vyadhi 2.Effect of Eranda taila on gut biomarkersTimepoint: 3 weeks	—

Countries

India

Contacts

Public ContactDr Sachin Rangrao Patil

Bharati Vidyapeeth Deemed to be university College of Ayurved Pune

umesh.tekawade@bharatividyapeeth.edu9423210319

Outcome results